Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Exclusion Criteria

• •1. patients who had received anti-vascular therapy;
• •2. Allergic to any ingredients of Apatinib;
• •3. Participated in other drug clinical researchers within four weeks;
• •4. Have a variety of factors that affect oral medication (such as can not swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.)
• •5. Severe infection;
• •6. Patients with serious cardiovascular diseases,such as unstable angina, grade 3-4 heart dysfunction (NYHA Standard), congestive heart failure, poor-controlled arterial hypertension despite standard medical management;
• •7. Patients who received major surgical operations within 4 weeks before screening;
• •8. Patients who manifested arterial/venous thrombus events, e.g.cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, etc., within 12 months before screening;
• •9. Past or concurrent with other malignancies, except for cured skin basal cell carcinoma and cervical in situ cancer;
• •10. Have a history of psychiatric abuse and can not quit or have mental disorders.